Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Enading Pay-to-Delay deals will save taxpayers billions of dollars… and may save some lives, too.

Posted in Generic Drugs, Politics

Pay-to-delay deals help no one and nothing outside of the bottom lines of a few big pharmaceutical companies.  Here’s hoping they go away soon…

FOR TOO LONG, pay-for-delay settlements have been an accepted part of the health-care landscape. In these deals, a brand-name drug manufacturer pays a generic competitor to delay its entry into the market. Sound illegal? It isn’t — but a provision to be considered by the Senate Appropriations Committee on Thursday would finally make it so, banning such settlements unless drug manufacturers could prove they were not anticompetitive. It’s a good idea that could save consumers billions of dollars.

Source: Ending ‘pay for delay’ tactics on generic drugs could mean lower prices